CODEXIS, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Nine Months Ended September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Operating activities: | ||
| Net loss | $(53,575) | $(54,900) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 3,891 | 3,737 |
| Reduction in the carrying amount of right-of-use assets | 2,178 | 2,364 |
| Stock-based compensation | 7,424 | 10,561 |
| Provision (recovery) for credit losses | (113) | — |
| Asset impairment and other charges | — | 165 |
| Impairment of investment in non-marketable securities | — | 3,910 |
| Non-cash interest expense | 929 | 611 |
| Amortization of discount on short-term investments | (931) | (1,009) |
| Other non-cash items | — | 11 |
| Changes in operating assets and liabilities: | ||
| Financial assets | 9,346 | 2,818 |
| Inventories | (137) | 582 |
| Prepaid expenses and other assets | (1,320) | 1,417 |
| Accounts payable | (493) | (1,339) |
| Accrued compensation and other accrued liabilities | (4,295) | 1,334 |
| Other long term liabilities | (2,318) | (3,064) |
| Deferred revenue | (54) | (140) |
| Net cash used in operating activities | (39,468) | (32,942) |
| Investing activities: | ||
| Purchase of property and equipment | (3,951) | (2,531) |
| Proceeds from sale of property and equipment | 5 | 84 |
| Purchases of short-term investments | (41,891) | (72,643) |
| Proceeds from maturity of short-term investments | 63,626 | 19,000 |
| Proceeds from sale of short-term investments | — | 1,973 |
| Net cash provided by (used in) investing activities | 17,789 | (54,117) |
| Financing activities: | ||
| Proceeds from exercises of stock options | 1,098 | 281 |
| Proceeds from issuance of stock under employee stock purchase plan | 317 | 525 |
| Proceeds from issuance of common stock in connection with equity sales agreements | 17,268 | 31,320 |
| Costs incurred in connection with equity sales agreements | (829) | (1,615) |
| Proceeds from long-term debt | 9,897 | 29,521 |
| Payment of debt issuance costs | (3) | (642) |
| Net cash provided by financing activities | 27,748 | 59,390 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | 6,069 | (27,669) |
| Cash, cash equivalents and restricted cash at the beginning of the period | 20,829 | 66,697 |
| Cash, cash equivalents and restricted cash at the end of the period | $26,898 | $39,028 |
| Supplemental disclosure of cash flow information: | ||
|---|---|---|
| Interest paid | $2,242 | $1,633 |
| Income taxes paid | $— | $17 |
| Supplemental non-cash investing and financing activities: | ||
| Capital expenditures incurred but not yet paid | $212 | $249 |
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the unaudited condensed consolidated balance sheets as of September 30, 2025 and 2024 to the total of the same such amounts shown above in the unaudited condensed consolidated statements of cash flows:
| September 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash and cash equivalents | $25,351 | $37,452 |
| Restricted cash, current and non-current | 1,547 | 1,576 |
| Total cash, cash equivalents and restricted cash | $26,898 | $39,028 |
This table excludes short-term investments of $33.4 million and $52.8 million as of September 30, 2025 and 2024, respectively. Total cash, cash equivalents, and short-term investments as of September 30, 2025 and 2024 were $58.7 million and $90.3 million, respectively.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.